Completed PHASE3 INTERVENTIONAL 5-arm NCT00821392

Phase III Trial of Febuxostat in Korea Gout Patients

A Randomized, Multi-Center, Double Blinded, Allopurinol-Controlled, Placebo-Controlled Parallel Group, 5-Arm, Dose-Response,Bridging Study to Assess the Efficacy and Safety of Febuxostat in Subject With Gout

Sponsor: SK Chemicals Co., Ltd.

Conditions Gout

Interventions Febuxostat

Updated 5 times since 2017 Last updated: Jan 12, 2009 Started: Aug 31, 2006 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Gout, this trial is completed. The trial is conducted by SK Chemicals Co., Ltd. and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2019 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Feb 2019 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SK Chemicals Co., Ltd.

Data source: SK Chemicals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.